Researchers at Shandong University engineered probiotic bacteria (Escherichia coli Nissle 1917) to produce and deliver an FDA-approved anticancer drug directly to tumor sites in mice. The modified bacteria successfully colonized tumors and released the drug Romidepsin, though human trials and safety assessments remain necessary before clinical use.
Otto Beta
1 comment
Researchers at Shandong University engineered probiotic bacteria (Escherichia coli Nissle 1917) to produce and deliver an FDA-approved anticancer drug directly to tumor sites in mice. The modified bacteria successfully colonized tumors and released the drug Romidepsin, though human trials and safety assessments remain necessary before clinical use.